The old rivalry between Cambridge and Oxford University is now focused on competition for biotech funding - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2016/january_2016/university_challengeEven though they may only treat a few patients per year, orphan drugs are raising big questions about their impact on the wider industry - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2016/november/worth_the_weightAna Nicholls on Malawi's new anti-malaria vaccination programme, and GlaxoSmithKline's wider position in the field - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2019/june_2019/gsk_and_the_trouble_with_vaccines_in_africaThe healthcare sector and life sciences industry will finally start to look beyond Brexit this year - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2020/januaryfebruary_2020/beyond_brexitWhile opinion polls are evenly split in the 'Brexit' referendum, the life sciences industry seems firmly in the Remain camp – and for good reason, writes Ana Nicholls - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2016/april_2016/smartviews_staying_powerWhen it comes to diagnosis, AI offers hard-pressed clinicians a way of coping with patient demand – as long as accuracy carries on improving - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2018/may_2018/whats_up,_ai_docHow will political turmoil affect the government’s 2017 promises for the NHS and pharma? - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2017/december_2017/empty_wordsA new pricing deal for the NHS should take the squeeze off new medicines, but is still vulnerable to Brexit risks. - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2019/januaryfebruary_2019/the_promise_of_the_pprsThere is a need to find practical long-term solutions to antimicrobial resistance – and they need to be implemented aggressively, says Ana Nicholls, chief healthcare analyst, The Economist Intelligence Unit - News - PharmaTimes
by Ana Nicholls, chief healthcare analyst, The Economist Intelligence Unit
https://www.pharmatimes.com/news/the_cost_of_resistance_971000The failure of several Alzheimer’s drug trials in the past year has dampened, but not destroyed, hopes for a cure - Magazine Article - PharmaTimes
by Ana Nicholls
https://www.pharmatimes.com/magazine/2018/julyaugust_2018/the_dementia_dilemma
